ArticleFrontiers in psychiatry2019
Beneficial Effects of GLP-1 Agonist in a Male With Compulsive Food-Related Behavior Associated With Autism.
Article in Frontiers in psychiatry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- The impact of glucagon-like peptide-1 (GLP-1) agonists in the treatment of eating disorders: a systematic review and meta-analysis.Eating and weight disorders : EWD · 2025Pooled it
- Article
- Reduced serum cortisol, IGF-1, GLP-1, and T3 levels in medication-free children and adolescents with obsessive-compulsive disorder: a case-control study.Frontiers in psychiatry · 2026Article
- Article
- Nutritional Factors and Therapeutic Interventions in Autism Spectrum Disorder: A Narrative Review.Children (Basel, Switzerland) · 2025Review
- Glucagon-like peptide-1 receptor agonists and mental health: a narrative review of emerging benefits and risks.Journal of Yeungnam medical science · 2025Article
- Glucagon-like peptide-1 receptor: mechanisms and advances in therapy.Signal transduction and targeted therapy · 2024 · on this mapReview
- Effects of GLP1 receptor analogues in obesity with neurodevelopmental disorder: case report of a patient with holoprosencephaly.European journal of clinical nutrition · 2024Article
- GLP-1 receptor agonists: A novel pharmacotherapy for binge eating (Binge eating disorder and bulimia nervosa)? A systematic review.Journal of clinical & translational endocrinology · 2024Review
- Assessment Methods for Problematic Eating Behaviors in Children and Adolescents With Autism Spectrum Disorder.Journal of the Korean Academy of Child and Adolescent Psychiatry · 2024Article
- Beyond Weight Loss: Added Benefits Could Guide the Choice of Anti-Obesity Medications.Current obesity reports · 2023Review
- Activation of glucagon-like peptide-1 receptors reduces the acquisition of aggression-like behaviors in male mice.Translational psychiatry · 2022Article
- Intergenerational Metabolic Syndrome and Neuronal Network Hyperexcitability in Autism.Trends in neurosciences · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Individuals with autism spectrum disorder (ASD) frequently display intensely repetitive, restricted thoughts, and behaviors. These behaviors have similarities to compulsions and/or obsessions in obsessive compulsive disorder (OCD) and are primarily treated with behaviourally-based interventions and serotonin uptake inhibitors (SSRIs). Due to the lack of treatment responses in many cases, however, new treatments are being sought. Here we report beneficial effects of treatment with liraglutide, a glucagon-like peptide-1 (GLP-1) analog, on severe obsessive food craving, binge eating, weight gain, and behavioral problems in an adolescent male with infantile autism and moderate intellectual impairment. Liraglutide treatment reduced weight and unwanted behavior seemingly by preventing food-related repetitive thoughts and compulsions. Our report provides clinical evidence that GLP-1 signaling pathway may represent a novel target for treating food-related behavioral problems and aggressive behavior in ASD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.